20:14 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate does not impair driving in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 106 showing that insomnia candidate lemborexant (E2006) given each night at bedtime met the primary endpoint of...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's insomnia candidate improves postural stability in Phase I

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase I Study 108 showing that both doses of insomnia candidate lemborexant (E2006) given each night at bedtime met the...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Company News

Indivior licenses preclinical addiction candidate from C4X Discovery

C4X Discovery Holdings plc (LSE:C4XD) licensed to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and is eligible for up to $284...
19:07 , Mar 29, 2018 |  BC Extra  |  Company News

C4X gains after addiction deal with Indivior

C4X Discovery Holdings plc (LSE:C4XD) jumped 56p (99%) to 112.5p after licensing to Indivior plc (LSE:INDV) exclusive, worldwide rights to C4X3256, a preclinical compound to treat addiction. C4X will receive $10 million up front and...
18:43 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Eisai, Purdue's lemborexant meets in Phase III for insomnia

Eisai Co. Ltd. (Tokyo:4523) and Purdue Pharma L.P. (Stamford, Conn.) reported top-line data from the Phase III SUNRISE 1 trial in about 1,000 patients ages 55 and older with insomnia showing that oral lemborexant (E2006)...
20:04 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

Designing specificity

Solving a key problem in the orexin field, C4X Discovery Holdings plc (LSE:C4XD) has described how its technology platform yielded an antagonist with selectivity for OX1R over OX2R and disclosed data for the compound in...
23:21 , Nov 10, 2016 |  BC Week In Review  |  Clinical News

Lemborexant: Ph II started

Eisai began the double-blind, placebo-controlled, international Phase II Study 202 to evaluate 2.5, 5, 10 and 15 mg oral lemborexant for 4 weeks in about 125 patients ages 65-90 with ISWRD and mild to moderate...
07:00 , Oct 13, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Orexin 2 receptor (OX2R; HCRTR2); OX1R (HCRTR1)

Neurology INDICATION: Addiction Rat studies suggest inhibiting OX2R could help treat relapse in cocaine addiction. In a rat model of cocaine addiction relapse, injection of an OX2R antagonist tool compound into the paraventricular nucleus of the thalamus...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Orexin 2 receptor (OX2R; HCRTR2)

Neurology INDICATION: Cataplexy; narcolepsy Cell culture and mouse studies identified an OX2R activator that could help treat cataplexy and narcolepsy. Screening of a small molecule library in a mammalian cell-based assay of OX2R-mediated calcium signaling and optimization...
07:00 , Aug 17, 2015 |  BioCentury  |  Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...